49
https://pubmed.ncbi.nlm.nih.gov/38091179
The pan-immune-inflammation value (PIV) can independently predict progression-free and overall survival in stage IIIB/C non-small-cell lung cancer patients undergoing concurrent chemoradiotherapy.
